Cannabis has been part of human culture for thousands of years, yet the molecular machinery that gives the plant its mind-altering and medicinal power has remained surprisingly obscure. Now a team of Dutch researchers has effectively turned back the evolutionary clock, resurrecting long extinct enzymes to show how cannabis first learned to make its signature compounds. By rebuilding these ancient proteins in the lab, they have traced the biochemical roots of the drug and opened a new frontier for precisely engineered cannabinoids.
The work reveals that the familiar molecules tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabichromene (CBC) did not appear fully formed, but emerged from a versatile ancestral system that later split into today’s highly specialized enzymes. I see this as a rare moment when evolutionary biology, plant chemistry, and drug development converge, with direct implications for how future medicines might be brewed not in greenhouses but in steel tanks.
The ancient puzzle behind THC, CBD, and CBC
Modern cannabis plants rely on three distinct enzymes to produce THC, CBD, and CBC, each tuned to channel a common precursor into a different cannabinoid. For THC, that job falls to a THC acid synthase, while CBD and CBC have their own dedicated synthases that shape the plant’s chemical profile and, ultimately, its effects on the human body. Researchers have now shown that these three branches can be traced back to a single ancestral enzyme system that once generated several cannabinoids at once, a finding that reframes the plant’s chemistry as the product of a long evolutionary experiment rather than a fixed design, as described in new work on the origins of these compounds.
For a plant that humans have been cultivating, smoking, weaving, eating, and arguing about for millennia, it is striking how recently scientists have been able to map this pathway in detail. The new research shows that, for modern cannabis, the production of THC, CBD, and CBC depends on three specialized enzymes that evolved from a more generalist ancestor, a conclusion supported by biochemical reconstructions that track how mutations gradually narrowed each enzyme’s role as cannabis evolved. That evolutionary story, in which a flexible ancestral protein diversified into the THC, CBD, and CBC machinery we know today, is laid out in analyses of how modern plants make these molecules and in detailed breakdowns of how cannabis builds them step by step from a shared starting point, as explained in work on how the plant makes THC, CBD, and.
Resurrecting enzymes from a vanished cannabis ancestor
To uncover how that ancestral system worked, Dutch researchers turned to a technique known as ancestral sequence reconstruction, which uses modern gene sequences to infer what ancient proteins must have looked like millions of years ago. By comparing the DNA that encodes today’s THC, CBD, and CBC synthases, they computationally rebuilt the likely sequence of their common ancestor, then synthesized that genetic blueprint and expressed it in a laboratory host so they could test the resulting enzyme directly. This approach allowed them to move beyond speculation and watch an ancient cannabis protein in action, a strategy that is central to the new findings on how specialized enzymes for CBC and other cannabinoids emerged.
The reconstructed enzymes turned out to be more versatile than their modern descendants, capable of generating multiple cannabinoid acids instead of being locked into a single product. Scientists at Wageningen University & Research used ancestral sequence reconstruction to show where familiar compounds such as THC, CBD, and CBC come from, demonstrating that early enzymes could generate several cannabinoids at once before later evolution carved out the dedicated THC, CBD, and CBC pathways. Their work, which explicitly asks where these well known cannabis compounds originate, uses this method to connect present day chemistry to a shared ancestral protein, as detailed in their explanation of where THC, CBD, and CBC come from.
What the resurrected enzymes reveal about cannabis evolution
By resurrecting long extinct enzymes and testing them in the lab, the researchers have reconstructed how cannabis acquired the ability to produce THC, CBD, and CBC in the first place. The ancestral proteins appear to have been biochemical generalists, less efficient at making any single cannabinoid but able to produce a broader mix, which would have given early cannabis plants a flexible chemical arsenal against pests, UV radiation, and other environmental pressures. Over evolutionary time, gene duplication and mutation then allowed some copies to specialize, sharpening their output into the potent THC, CBD, and CBC synthases that dominate modern strains, a trajectory that has been pieced together by scientists tracing how these familiar compounds evolved.
The experiments show that these ancient enzymes are not just historical curiosities but working catalysts that can still churn out cannabinoid acids when expressed in modern cells. By reconstructing extinct enzymes from millions of years ago, researchers have demonstrated that cannabis evolved the ability to produce THC through a series of incremental changes, each step nudging the ancestral protein toward greater specificity and potency. That evolutionary path, from a broad spectrum enzyme to the tightly focused THC machinery, has been highlighted in discussions of how THC production emerged and in broader analyses that emphasize how the resurrected enzymes are less specialized than their modern counterparts, as described in work showing that these ancestral proteins were more generalist than their highly specialized descendants.
Dutch scientists and the search for new pain relief
The project is rooted in the Netherlands, where Dutch scientists at Wageningen University & Research have taken a leading role in decoding cannabis evolution and its pharmaceutical potential. Researchers at this institution have identified an ancient cannabis enzyme with promising pain relief properties, suggesting that some ancestral variants may favor cannabinoids with strong anti inflammatory and analgesic effects rather than the intense psychoactivity associated with THC. Their work points to specific cannabinoid profiles that could be harnessed for chronic pain and inflammatory conditions, as described in reports that Dutch researchers at Wageningen University & Research have discovered an ancient enzyme with notable anti inflammatory and pain relieving effects.
To address long standing gaps in our understanding of cannabinoid biosynthesis, the team combined ancestral sequence reconstruction with heterologous expression, inserting the inferred ancient genes into host organisms so they could be produced and studied at scale. By resurrecting and functionally characterizing these ancestral enzymes, they have not only clarified how THC, CBD, and CBC arose but also created a toolkit for future medicinal applications that could bypass the variability of whole plant extracts. The researchers themselves describe how they used this combined strategy to explore new therapeutic possibilities, a point underscored in their account of how they resurrected ancestral cannabis enzymes with an eye toward future medicinal applications.
From evolutionary curiosity to cannabinoid factories
What makes this work more than an evolutionary detective story is its direct relevance to how future cannabinoids might be produced. Scientists have now shown that these ancient enzymes can be repurposed as biotechnological tools, potentially turning microbes or cultured cells into miniature cannabinoid factories that generate specific THC, CBD, or CBC derivatives on demand. Dutch researchers who recreated ancient cannabis enzymes to trace THC and CBD origins have emphasized that understanding how specialized enzymes came to be is also a roadmap for engineering them, a point made clear in their description of how scientists recreated these enzymes to follow THC and CBD back to their origins.
From my perspective, the most striking implication is that the plant itself may become optional for many future cannabinoid based therapies. Scientists at Wageningen University have highlighted how cannabis evolved the ability to produce THC, CBD, and CBC, showing that early enzymes could generate several cannabinoids at once and that this versatility can now be harnessed in controlled systems. Their account of how scientists uncovered these ancient origins underscores that the same evolutionary logic that once diversified cannabinoids in wild plants can now be used to design safer, more targeted compounds in the lab, potentially reshaping everything from pain management to how regulators think about cannabis derived drugs.
More from Morning Overview